Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Anacor Pharma Prices Public Offering Of 3.13 Mln Shares At $6.39/shr

RELATED NEWS
Trade ANAC now with 

Anacor Pharmaceuticals (ANAC: Quote) announced that it has priced an underwritten public offering of 3.13 million shares of its common stock at a price to the public of $6.39 per share for gross proceeds of $20.0 million.

Anacor has also granted the underwriters a 30-day option to purchase up to 15 percent of the shares of common stock offered in the public offering to cover over-allotments.

The company said it expects to use the net proceeds from the sale of the shares for research and development activities, working capital and general corporate purposes. All of the shares in the offering will be sold by Anacor. The offering is expected to close on May 1, 2013, subject to satisfaction of customary closing conditions.

Cowen and Company, LLC is acting as the sole book-running manager for the offering. Canaccord Genuity Inc. and Wedbush Securities Inc. are acting as co-managers for the offering.

Click here to receive FREE breaking news email alerts for Anacor Pharmaceuticals, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.